Welcome to our dedicated page for Mersana Therapeutics news (Ticker: MRSN), a resource for investors and traders seeking the latest updates and insights on Mersana Therapeutics stock.
Mersana Therapeutics Inc (MRSN) is a clinical-stage biopharmaceutical pioneer developing antibody-drug conjugates (ADCs) through its proprietary Fleximer platform. This page serves as the definitive source for verified news and regulatory updates about their innovative cancer therapies.
Investors and researchers will find timely updates on clinical trial progress, partnership announcements, and scientific advancements across MRSN's ADC platforms. Our curated feed includes press releases about Dolasynthen payload optimization, Immunosynthen immune activation studies, and strategic collaborations advancing oncology pipeline candidates.
All content undergoes strict verification to ensure accuracy in reporting trial phases, regulatory milestones, and business developments. Bookmark this page for centralized access to MRSN's latest ADC research breakthroughs, presented with context for both professional investors and therapeutic area specialists.
Mersana Therapeutics (NASDAQ: MRSN) announced positive initial clinical data from Phase 1 trial of emiltatug ledadotin (Emi-Le), targeting B7-H4 in cancer treatment. The trial enrolled 130 patients with advanced/metastatic cancers, including triple-negative breast cancer (TNBC).
Key findings show Emi-Le was generally well-tolerated with no Grade 4 or 5 treatment-related adverse events. At intermediate doses (38.1-67.4 mg/m2), confirmed objective response rate was 23% across B7-H4 high tumors and TNBC patients previously treated with topo-1 ADCs. The company has initiated expansion in TNBC patients at 67.4 mg/m2 dose.
Notable safety profile includes no dose-limiting treatment-related neutropenia, neuropathy, ocular toxicity, or thrombocytopenia. Common treatment-related adverse events included AST increase (38%), proteinuria (31%), nausea (29%), and fatigue (28%).
Mersana Therapeutics (NASDAQ: MRSN) reported Q3 2024 financial results and provided business updates. The company ended Q3 with $155.2 million in cash, expecting to fund operations into 2026. Q3 revenue was $12.6 million, up from $7.7 million in Q3 2023. Net loss decreased to $11.5 million ($0.09 per share) from $41.7 million ($0.35 per share) year-over-year. The company plans to announce initial clinical data for XMT-1660 by year-end 2024 and is advancing Phase 1 trials for both XMT-1660 and XMT-2056. Mersana achieved milestone payments of $8 million from Johnson & Johnson and $1 million from Merck KGaA collaborations.
Mersana Therapeutics (NASDAQ: MRSN), a clinical-stage biopharmaceutical company developing antibody-drug conjugates for cancer treatment, has scheduled its Q3 2024 financial results and business updates conference call for November 13, 2024 at 8:00 a.m. Eastern Time. Investors can access the call via domestic (833-255-2826) or international (412-317-0689) dial-in numbers. A webcast will be available on the company's website, with a replay accessible for approximately 90 days following the presentation.
Mersana Therapeutics (NASDAQ: MRSN) provided a business update and reported Q2 2024 financial results. Key highlights include:
- Advancing Phase 1 trials for XMT-1660 and XMT-2056
- Expecting initial XMT-1660 clinical data and expansion initiation in H2 2024
- $162.7 million cash position as of June 30, 2024
- Capital resources expected to support operations into 2026
- Q2 2024 net loss of $24.3 million ($0.20 per share)
- Collaboration revenue of $2.3 million
- R&D expenses decreased to $17.2 million
- G&A expenses reduced to $10.5 million
- Earned $8 million milestone from Johnson & Johnson collaboration
The company continues to progress its ADC pipeline and collaborations while benefiting from reduced operating expenses.
Mersana Therapeutics (NASDAQ: MRSN), a clinical-stage biopharmaceutical company developing antibody-drug conjugates (ADCs) for cancer treatment, has announced its upcoming second quarter 2024 financial results and business update conference call. The event is scheduled for Tuesday, August 13, 2024, at 8:00 a.m. Eastern Time. Investors and interested parties can access the call via phone or webcast. The webcast will be available on the company's website for approximately 90 days following the conference call.
Mersana Therapeutics (NASDAQ: MRSN), a clinical-stage biopharmaceutical firm, will present at two upcoming investor conferences. These include the TD Cowen 5th Annual Oncology Innovation Summit on May 29, 2024, at 9:00 a.m. ET, and the Goldman Sachs 45th Annual Global Healthcare Conference on June 12, 2024, at 8:00 a.m. ET. The company specializes in developing antibody-drug conjugates (ADCs) targeting cancers with high unmet medical needs.
Mersana's proprietary ADC platforms, Dolasynthen and Immunosynthen, support a pipeline of product candidates such as XMT-1660 and XMT-2056. Live webcasts and archived replays of these events will be accessible on Mersana's website for 90 days post-event.
Mersana Therapeutics, a clinical-stage biopharmaceutical company, provided a business update and reported financial results for the first quarter of 2024. They are advancing Phase 1 clinical trials for XMT-1660 and XMT-2056, expecting to share initial data and initiate expansion. They continue collaborations and presented data showing platform differentiation. Financially, they have sufficient capital resources into 2026, with collaboration revenue increasing year-over-year.
Mersana Therapeutics, a clinical-stage biopharmaceutical company, granted an inducement award to a new employee on May 1, 2024, under Nasdaq Listing Rule 5635(c)(4). The award consists of a restricted stock unit (RSU) to acquire 35,100 shares of common stock, vesting over four years.
Mersana Therapeutics, a clinical-stage biopharmaceutical company, will host a conference call on May 9, 2024, to provide business updates and report financial results for the first quarter of 2024. The company focuses on developing antibody-drug conjugates targeting cancers with high unmet medical needs.
FAQ
What is the current stock price of Mersana Therapeutics (MRSN)?
What is the market cap of Mersana Therapeutics (MRSN)?
